Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
SenzaGen AB
SenzaGen AB
Activities:
Regulatory
Analysis
Pharmaceutical
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
SenzaGen and MB Research Labs sign toxicology agreement
With new legislature, animal-free <em>in vitro</em> toxicological testing is a growing market in the US. This collaboration taps into this market
Analysis
Next-generation safety testing
In vitro genetic testing offers an ethical alternative to animal testing, which is also cheaper, faster and more reliable
Pharmaceutical
Swedish SenzaGen teams up with Chinese animal-free testing specialist
The partnership comes at a time when a ban on animal experiments is expected
SenzaGen strengthens its organisation with IR and communications director
Recruitment
SenzaGen recruits Business Development Director
Research & Development
Collaboration tackles respiratory irritancy hazard
SenzaGen and AstraZeneca will develop a new genomic signature to distinguish allergens from irritants in the respiratory tract
Subscribe now